Table 1.

A Summary of Studies on Biomarkers and SCD.

BIOMARKER	PUBLICATION	POPULATION	RISK	PERIOD
C-reactive protein	2002 (34)	97/192 ♂	RR 2.65 (0.79-8.83)*	17
hsCRP	2009 (42)	99/294 ♀	n.s.*	16
hsCRP	2010 (44)	50/100 ♂	n.s‡	10
NT-proBNP	2009 (42)	99/294 ♀	RR 1.49 (1.09-2.05)*	16
NT-proBNP	2011 (50)	289/ ♂, ♀	HR 2.5 (1.6-3.8)∥	16
NEFA	2001 (52)	91/ ♂	RR 1.70 (1.21-2.13)†	22
LCn3FA	2002 (53)	94/184 ♂	RR 0.19 (0.05-0.71)*	17
TC	1995 (33)	106/ ♂	RR 1.48§	8
TC, TG, LDL, HDL	2002 (34)	97/192 ♂	n.s.*	17
Homocystein	2002 (34)	97/192 ♂	n.s.*	17
Magnesium	2010 (58)	264/ ♂, ♀	HR 0.62 (0.42-0.93)*	12
Magnesium	2010 (59)	505/ ♀,	RR 0.23 (0.09-0.60)*	26
Glucose	2005 (15)	2040/3800 ♂, ♀	OR 1.20 (1.12-1.28)†	14
Cystatin C	2009 (61)	91/ ♂, ♀	HR 2.67 (1.33-5.35)‡	12
Interleukin 6	2010 (44)	50/100 ♂	HR 3.06 (1.20-7.81)‡	10
Fibrinogen	2010 (44)	50/100 ♂	n.s‡	10
Fibrinogen	2009 (55)	207/ ♂, ♀	RR 2.56 (1.76-3.73)‡	12
vWf	2009 (55)	207/ ♂, ♀	RR 2.67 (1.80-3.96)‡	12
Factor VIIIc	2009 (55)	207/ ♂, ♀	RR 2.58 (1.77-3.78)‡	12

The table summarizes existing larger studies on biomarkers and risk of SCD that have reported risk variables including confidence intervals and P-values. Publication denotes year published and the number in the reference list. Population denotes number of cases/controls and gender.

Period indicates the follow-up period in years.

^*highest versus lowest quartile

^†per 1 SD increment

^‡highest versus lowest tertile

^§per 1 mmol/L increase

^∥highest versus lowest quintile

RR=relative risk, OR=odds ratio, HR=hazard ratio, n.s.=non significant, ♂=male, ♀=female, hsCRP=highly sensitive C-reactive protein, NT-proBNP= N-terminal pro B-type natriuretic peptide, NEFA= Nonesterified free fatty acids, LCn3FA= long-chain n–3 fatty acids, TC= total cholesterol, TG= triglyceride, LDL=LDL cholesterol, HDL= HDL cholesterol, vWf= von Willebrand factor